Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 1(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07327307Recruiting

Real World Evidence Study of SYN023 in Children Exposed to Rabies

Role: lead

NCT07342257Phase 1Completed

SYN023 With Rabies Vaccine in Healthy Pediatric Subjects

Role: lead

NCT04644484Phase 3Completed

A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety

Role: lead

NCT04495569Phase 1Completed

A Bridging Study of the SYN023 on Healthy Adult Subjects

Role: lead

All 4 trials loaded